March decisions signal momentum in rare disease demand, B-cell targeting and prevention policy.
Australia’s reimbursement gatekeeper has delivered a trio of decisions that could recalibrate rheumatology practice.
The Pharmaceutical Benefits Advisory Committee backed a new B-cell option in lupus nephritis, unlocked long-awaited access for familial Mediterranean fever (FMF) and widened the prevention lens through respiratory syncytial virus (RSV) coverage.
The PBAC’s March meeting recommended the PBS listing change for obinutuzumab in lupus nephritis.
In its considerations, the PBAC accepted that the anti-CD20 monoclonal antibody improved renal response outcomes compared with standard care alone, while also recognising the ongoing unmet need for more effective therapies in a population at high risk of progression and complications.
The decision supports subsidised access for a defined cohort, reflecting both clinical demand and stakeholder input, and positions obinutuzumab alongside existing immunosuppressive strategies in a setting where disease control remains challenging and relapse rates high.
It what is likely to be even more striking for many rheumatologists is the committee’s recommendation for canakinumab in colchicine-resistant or intolerant FMF, a rare autoinflammatory condition long characterised by a scarcity in therapeutic options.
The PBAC explicitly acknowledged the unmet clinical need in rare diseases across its deliberations, and the FMF decision reflects that broader stance, with access to an IL-1β inhibitor expected to address a cohort with limited or no effective alternatives.
The implication was clear – after years of reliance on colchicine with suboptimal control in refractory patients, pent-up demand is likely to translate rapidly into uptake if the recommendation proceeds to PBS listing, particularly given the burden of recurrent flares and risk of amyloidosis in inadequately treated disease.
Beyond therapeutics, the meeting also signalled continued expansion of RSV prevention policy, with recommendations supporting vaccine access changes under national programs.
The broader RSV coverage has direct relevance for immunosuppressed populations, including patients receiving biologics and targeted therapies, where infection risk remains a persistent concern.
The decision builds on earlier vaccination strategies and reflects increasing recognition of RSV as a significant cause of morbidity in older and immunocompromised populations.
Alongside this, the PBAC supported a practical update to one of rheumatology’s most widely used biologics, recommending new high-concentration, lower-volume formulations of adalimumab.
The decision introduces 40mg/0.4 mL and 20mg/0.2 mL presentations to the PBS, aligning listings with currently registered products and contemporary prescribing practice.
While therapeutically equivalent to existing formulations, the reduced injection volume is expected to improve patient experience, particularly for those on long-term therapy for conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
Related
Another recommendation from the PBAC that has been watched with interest and has caused a national stir was the committee’s positive recommendation for tirzepatide (Mounjaro) for the treatment of type 2 diabetes.
Within minutes of the committee’s report coming out, Eli Lilly announced it would “regretfully” not be proceeding with its quest for PBS listing. The pharma company said it made the decision after it was unable to secure a viable funding recommendation for the drug.
“We do not make this decision lightly. After four reimbursement submissions and extensive departmental engagement over three years, we were left with no other option,” said Manny Simons, general manager of Lilly Australia and New Zealand.
“We understand how disappointing this will be for up to 450,000 Australians living with type 2 diabetes who should have access to Mounjaro through the PBS.”
Read more about this and the reaction from Australian experts in Rheumatology Republic.
See the full outcomes report from the PBAC March meeting here.
